Katherine Atkinson - Evofem Biosciences Chief Officer
Insider
Katherine Atkinson is Chief Officer of Evofem Biosciences
| Phone | 858 550 1900 |
| Web | https://www.evofem.com |
Evofem Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.2475) % which means that it has lost $1.2475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8727) %, meaning that it created substantial loss on money invested by shareholders. Evofem Biosciences' management efficiency ratios could be used to measure how well Evofem Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Evofem Biosciences currently holds 125.74 M in liabilities with Debt to Equity (D/E) ratio of 8.72, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evofem Biosciences has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Evofem Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evofem Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evofem Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evofem to invest in growth at high rates of return. When we think about Evofem Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| FCCP MD | Bright Minds Biosciences | 61 | |
| Thomas III | iBio, Common Stock | 57 | |
| III CFA | Checkpoint Therapeutics | 46 | |
| Mike Jenkins | iBio, Common Stock | N/A | |
| Stephen Kilmer | iBio, Common Stock | N/A | |
| Randy Maddux | iBio, Common Stock | 63 | |
| Robert McRae | Palisade Bio | N/A | |
| Brian Kevany | Abeona Therapeutics | N/A | |
| Ian McDonald | Bright Minds Biosciences | 37 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
| John Cini | Sonnet Biotherapeutics Holdings | 72 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| MD FACP | Sonnet Biotherapeutics Holdings | 67 | |
| Scott Santiamo | Abeona Therapeutics | N/A | |
| Melissa Berquist | iBio, Common Stock | N/A | |
| Alexander Fudukidis | Affimed NV | N/A | |
| Daniel MD | Tonix Pharmaceuticals Holding | N/A | |
| Jason Davis | Virax Biolabs Group | 53 | |
| Angus Smith | Affimed NV | 42 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Joseph Vazzano | Abeona Therapeutics | 40 | |
Management Performance
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 |
Evofem Biosciences Leadership Team
Elected by the shareholders, the Evofem Biosciences' board of directors comprises two types of representatives: Evofem Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evofem. The board's role is to monitor Evofem Biosciences' management team and ensure that shareholders' interests are well served. Evofem Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evofem Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Justin File, Chief Officer | ||
| Katherine Atkinson, Chief Officer | ||
| Saundra Pelletier, Pres Chair | ||
| Amy Raskopf, VP Relations | ||
| Kathy GalloDoyle, VP Sales | ||
| Karina Fedasz, Head Devel |
Evofem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Evofem Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (5.41) % | ||||
| Current Valuation | 112.69 M | ||||
| Shares Outstanding | 121.22 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Number Of Shares Shorted | 8.68 M | ||||
| Price To Earning | (1.26) X | ||||
| Price To Book | 8.37 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |